Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

SomnoMed (ASX:SOM) FY26 Results: Revenue Reaches AUD 114.5mn as EBITDA Rises 19%

SomnoMed (ASX:SOM) reported higher FY26 revenue and EBITDA while expandingManufacturingcapacity, reducing production times and progressing the commercial rollout of its oral appliance portfolio.

Aditi Sarkar | 28 August 2026

CleanSpace Holdings (ASX:CSX) Holds FY26 Revenue at AUD 19.8mn as AGILE Opens New Respirator Markets

CleanSpace Holdings Limited (ASX:CSX) finished FY26 with revenue broadly unchanged at AUD 19.8mn as regional market conditions and regulatory changes affected sales. At the same time, the company launched its AGILE loose-fitting powered air-purifying respirator, expanded its addressable market and maintained AUD 10.1mn of …

Aditi Sarkar | 28 August 2026

Resonance Health (ASX: RHT) Returns to Profit as SaMD Pipeline and Clinical Demand Open New Growth Paths

Resonance Health Limited (ASX: RHT) has entered FY27 from a different financial position, having returned to full-year profitability while expanding its imaging, clinical research and investigator-site businesses. The FY26 result shows aBusinessmoving from a single revenue source towards three complementary operations, supported by recurring …

Aditi Sarkar | 28 August 2026

Clinuvel’s Decade of Profitability Meets U.S. Expansion — Could the Nasdaq Push Trigger a New Chapter?

The headline figures underline the durability of the model. Clinuvel reportedRevenueof around $94.0 million, while cash reserves rose 12% to approximately $252 million. That combination of profitability and a strengtheningBalance Sheetgives the company something many peers lack: the ability to fund its own ambitions …

Sonal Goyal | 27 August 2026

Clarity Pharma Reports More Complete Cancer Responses — Could Copper-67 Become Its Breakthrough Catalyst?

Complete responses, where signs of the targeted cancer are no longer detectable by the trial’s measures, are the kind of result that tends to draw attention. It is important, however, to keep the context in mind. These are early-stage trial observations in a defined …

Sonal Goyal | 27 August 2026

Mesoblast’s Next Big Catalyst Is Here: Could Its Phase 3 Trial Milestone Change the Story for MSB?

That matters because completing treatment sets the clock ticking toward a data readout, which investors typically view as a major potential catalyst. Whether the results are positive or not remains entirely unknown, and it would be premature to assume any particular outcome. Late-stage trials …

Sonal Goyal | 27 August 2026

Sigma Healthcare (ASX:SIG) Strengthens Earnings Profile with FY26 Revenue and EBIT Growth

Sigma Healthcare (ASX:SIG) has reported its FY26 financial results, marking its first full financial year following theMergerwith Chemist Warehouse Group (CWG). The company delivered double-digitRevenueandEarningsgrowth, expanded its pharmacy network and continued progress on integration initiatives. Sigma Healthcare (ASX:SIG) shares closed at AUD 2.62 on …

Aditi Sarkar | 27 August 2026

CSL (ASX: CSL): CSL Bucks the ASX Sell-Off - Is Australia's Healthcare Giant Finally Turning the Corner?

CSL shares surged after a FY26 result that buried a USAUD 2.6bn statutory loss beneath a credible reset story, above-consensus profit guidance and a fresh buyback - but the turnaround is a promise, not yet a fact.

Aditi Sarkar | 27 August 2026

Cochlear (ASX: COH): Cochlear Shares Retreat - Is This Healthcare Champion Becoming Too Cheap to Ignore?

After a brutal 2026 that saw Cochlear shares collapse from above AUD 300 to a 52-week low following a shock profit downgrade, the hearing-implant leader delivered an FY26 result at the top of its revised guidance, sparking a relief rally and reopening the debate …

Aditi Sarkar | 27 August 2026
Support

Hi! How can we help you today?

Loading…